Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: HIV Infections, Sexually Transmitted Diseases, Pregnancy
Interventions: Full Parent communication intervention, Brief Parent Communication Intervention, Control Parent Intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 9 Years to 12 Years
Enrollment: 2,210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2006
U.S. locations: 3
States / cities: Little Rock, Arkansas • Athens, Georgia • Atlanta, Georgia

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 24 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions: Zidovudine, Tocilizumab, Valganciclovir (VGC); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Catheter-Related Infections
Interventions: Mino-Lok Therapy (MLT); Drug
Lead sponsor: Leonard-Meron Biosciences, Inc.; Industry
Eligibility: 12 Years and older
U.S. locations: 27
States / cities: Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 21 more

Conditions: Intermediate Uveitis, Posterior Uveitis
Interventions: dexamethasone, Sham injection; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Carbapenem-Resistant Enterobacteriaceae
Interventions: Rectal swab collection; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana • Detroit, Michigan

Conditions: HIV Infections
Interventions: Thiamine hydrochloride, Riboflavin, Ascorbic acid, Vitamin E; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Denver, Colorado • Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 49
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 33 more

Conditions: Herpes Labialis
Interventions: iontophoretic acyclovir; Device
Lead sponsor: Transport Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Chronic Hepatitis C
Interventions: LDV/SOF FDC; Drug
Lead sponsor: Peter J. Ruane, M.D., Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Antimicrobial Stewardship, Acute Bronchitis, Upper Respiratory Infection
Interventions: Antibiotic Stewardship; Behavioral
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Peripheral Nervous System Diseases
Interventions: Acetyl-L-carnitine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 10
States / cities: Palo Alto, California • Atlanta, Georgia • Honolulu, Hawaii + 5 more

Conditions: Encephalitis, Japanese Encephalitis
Interventions: ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 16
States / cities: Burbank, California • Costa Mesa, California • Davis, California + 13 more

Conditions: Group A Streptococcal Infection
Interventions: Strepic® Device; Device
Lead sponsor: David A. Talan; Other
Eligibility: 7 Years to 64 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Surgical Site Infection, Obesity, Diabetes, Cesarean Section Complications
Interventions: Negative Pressure Wound Therapy; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Iowa City, Iowa + 1 more

Conditions: Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Interventions: Transcu O2®; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Labor
Interventions: Observation; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: raltegravir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Candidiasis, Esophageal, HIV Infections
Interventions: Itraconazole, Fluconazole; Drug
Lead sponsor: Janssen Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 33
States / cities: North Little Rock, Arkansas • Bakersfield, California • Rialto, California + 26 more

Conditions: HIV Infections
Interventions: Emtricitabine, Lamivudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: St. Petersburg, Florida • Great Neck, New York

Conditions: Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions: Valacyclovir; Drug
Lead sponsor: G.V. (Sonny) Montgomery VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Sulfamethoxazole-Trimethoprim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 40
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more

Search by objective public record fields.

Parents Matter!: Interventions to Promote Effective Parent-Child Communication

HIV Treatment-Readiness Measure (HTRM) Validation

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.

A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV Drugs

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Pilot Study of Strepic® Device for the Diagnosis of Group A Streptococcal Pharyngitis

SUpPress SSI - Single Use Negative Pressure Wound Therapy (NPWT) to Reduce Surgical Site Infections

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

Electromyography in Labor and Parturition

Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing

Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis